Miraculins Completes Share Consolidation
24 Janvier 2014 - 10:30PM
Marketwired
Miraculins Completes Share Consolidation
WINNIPEG, MANITOBA--(Marketwired - Jan 24, 2014) - Miraculins
Inc. (TSX-VENTURE:MOM) ("Miraculins" or the "Company"), a medical
diagnostic company focused on acquiring, developing and
commercializing diagnostic and risk assessment technologies for
unmet clinical needs, announces that, further to its news release
of January 13, 2014, the TSX Venture Exchange has approved the
consolidation of the Company's issued and outstanding common shares
("Common Shares") on the basis of ten pre-consolidation Common
Shares for every one post-consolidation Common Share and the
Company has proceeded with the consolidation. Effective at the
opening of the market on January 27, 2014, Miraculins' shares will
commence trading on the TSX Venture Exchange on a consolidated
basis under the new CUSIP number 60462L207. The Company's name and
trading symbol will not change as a result of the consolidation.
The Company will have approximately 12,492,010 Common Shares issued
and outstanding as a result of the consolidation. Letters of
transmittal with respect to the consolidation will be sent to
registered shareholders by CST Trust Company, the Company's
Transfer Agent.
About Miraculins Inc.
Miraculins is a medical diagnostic company focused on acquiring,
developing and commercializing non-invasive technologies for unmet
clinical needs. A significant number of promising diagnostic
opportunities remain un-commercialized because of the sizable gap
between the discovery stage, when research institutions are
typically involved, and the commercialization stage, when the
larger commercial enterprises become interested. Miraculins has
direct experience in bridging this gap. The Company's PreVu® POC
Test is a revolutionary new coronary artery disease risk assessment
technology that measures cholesterol levels in a patient's skin
non-invasively, painlessly and without the need for fasting. The
Company's Scout DS® system is the first non-invasive diabetes
testing system designed to provide a highly sensitive and
convenient method for measuring diabetes related biomarkers in the
skin, the accumulation of which are accelerated by abnormal blood
sugar levels and oxidative stress. Unlike current testing methods,
a Scout DS® test requires no blood draw, no fasting, and no waiting
for a lab result. The product has been used and validated in
thousands of patients around the world. The Company's preeclampsia
program is partnered with Alere Inc., one of the world's largest
diagnostic companies. For more information visit
www.miraculins.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
PreVu® and SCOUT DS® are registered
trademarks of Miraculins Inc. All Rights Reserved. 2014.
Miraculins Inc.Christopher J. MoreauPresident &
CEO204-477-7599204-453-1546info@miraculins.comwww.miraculins.com
Miraculins Inc. (TSXV:MOM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Miraculins Inc. (TSXV:MOM)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about (TSX Venture Exchange): 0 recent articles
Plus d'articles sur Miraculins Inc.